Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus ...

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...
GlobalData on MSN

HUTCHMED begins Phase III segment of metastatic PDAC treatment trial

HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...
Stocktwits on MSN

IMRX stock closed over 20% higher today: Here’s why

Immuneering Corporation (IMRX) on Wednesday said that its experimental drug improved overall survival in a mid-stage trial in ...
Medscape

Weekly Nab-Paclitaxel Shows Modest Advantage in High-Risk HR+/HER2– Early Breast Cancer

Final survival results from the WSG ADAPT hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) chemotherapy trial demonstrated that weekly nanoparticle ...
Targeted Oncology

Quadruplet Regimen With Penpulimab and Anlotinib Extends PFS in Metastatic Pancreatic Cancer

The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...
ascopubs.org

NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study The GeparSepto trial ...

Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3

Immuneering (NASDAQ:IMRX) provided an update from its ongoing Phase 2A trial of atebumetanib plus modified gemcitabine and ...
ascopubs.org

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database A safety cohort ...
Nasdaq

Corcept Therapeutics Initiates Phase 2 Trial Of Relacorilant For Ovarian Cancer

(RTTNews) - Corcept Therapeutics Incorporated (CORT), Monday announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in ...
Business Wire

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...